-

01:06:38 PM

PRLD Stock News

PRLD - Prelude Therapeutics Inc

08/29/23 8:30 AM

Nasdaq : PRLD

conferenceslow float

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows: Wells Fargo 18

RHEA-AI

neutral

08/03/23 8:00 AM

Nasdaq : PRLD

earningslow float

Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Prelude Therapeutics

RHEA-AI

neutral

05/31/23 8:30 AM

Nasdaq : PRLD

conferenceslow float

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will participate in the Jefferies Healthcare Conference, taking place in New York City, June 7 to 9, 2023.

RHEA-AI

neutral

05/18/23 7:00 AM

Nasdaq : PRLD

offeringlow float

Prelude Therapeutics Announces Pricing of Public Offering

Prelude Therapeutics Incorporated ("Prelude" or the "Company") (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its underwritten public offering of 3,048,522 shares of its voting common stock and

RHEA-AI

neutral

05/17/23 4:08 PM

Nasdaq : PRLD

offeringlow float

Prelude Therapeutics Announces Launch of Proposed Public Offering

Prelude Therapeutics Incorporated (“Prelude” or the “Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it has commenced an underwritten public offering of $100.0 million of shares of common stock and, in

RHEA-AI

neutral

05/08/23 8:30 AM

Nasdaq : PRLD

earningslow float

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology

RHEA-AI

neutral

04/27/23 8:30 AM

Nasdaq : PRLD

conferenceslow float

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows: H. C.

RHEA-AI

neutral

04/11/23 8:30 AM

Nasdaq : PRLD

conferenceslow float

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced details relating to eight abstracts being presented at the

RHEA-AI

neutral

03/15/23 8:30 AM

Nasdaq : PRLD

earningslow float

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

Four differentiated clinical compounds progressing through Phase 1 towards key data milestones Eight abstracts accepted for presentation at the 2023 American Association for Cancer Research (AACR) Annual Meeting Cash balance of $201.7 million as of December 31, 2022; runway remains unchanged

RHEA-AI

positive

03/15/23 8:00 AM

Nasdaq : PRLD

clinical triallow float

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in

RHEA-AI

neutral

PRLD Data

IndustryPharmaceutical Preparation Manufacturing
Websitepreludetx.com
Security namePrelude Therapeutics Inc
SectorManufacturing
Tags
- Health Technology
- Biotechnology

About Prelude Therapeutics Inc

prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.